MIND MEDICINE MINDMED INC. [MMEDF: OTCQB]

3.32 -0.12 (-3.49%) 02/26/2021 Delayed 15 minutes

Open	$3.54	Daily Range	$3.15-$3.54
Prev. Close	$3.44	52 Week Range	$0.0833-$5.07
Volume	2,457,597

Quote Data Realtime

Inside Quote
Bid	Ask	Last Inside Change
$3.31 x 525 shares	$3.32 x 9212 shares	02/26 5:00 PM EST

Level II Quote Montage

BID

ASK

MMID	Bid Price	Bid Size	Date/Time
CDEL	3.31	525	02/26
GTSM	3.30	2616	02/26
NITE	3.30	1550	02/26
ETRF	3.30	847	02/26
INTL	3.30	300	02/26
VALX	3.29	5800	02/26
JANE	3.29	5000	02/26
OTCX	3.29	9200	02/26
CSTI	3.28	100	02/26
VNDM	2.99	6000	02/26
PAUL	2.88	100	02/23
MAXM	2.71	8900	02/26
LAFC	2.52	100	12/22
VERT	1.97	100	01/28
PUMA	1.42	100	02/26
BGCE	1.00	100	02/23
WABR	1.00	100	02/01
MCAP	0.80	1000	02/26
cCANT	2.52	100	02/23

MMID	Ask Price	Ask Size	Date/Time
NITE	3.32	8253	02/26
CSTI	3.32	959	02/26
OTCX	3.34	1500	02/26
INTL	3.34	800	02/26
ETRF	3.35	100	02/26
VALX	3.36	2900	02/26
JANE	3.38	5000	02/26
CDEL	3.38	1000	02/26
GTSM	3.40	800	02/26
MAXM	3.50	100	02/26
VNDM	3.50	100	02/26
PAUL	4.50	100	02/17
VERT	5.00	100	01/22
PUMA	5.44	100	02/26
LAFC	5.45	100	12/14
MCAP	5.86	100	02/26
BGCE	5.98	100	02/23
WABR	100.00	100	02/12
cCANT	6.00	100	01/21

The quotes displayed here are published by market makers on the OTC Markets Group Inc. electronic inter-dealer quotation and trading system for OTC securities. Please see Terms of Service and Risk Warning for more information.

MMID - Market maker quotation published in OTC Link that meets the Inside market | MMID - Market maker quotation published in OTC Link | cMMID - Closed quote | Unpriced - Unpriced quote in OTC Link | MMIDu - Unsolicited market maker quotation published in OTC Link

Breakthrough Mental Healing

We help patients unlock the healing power of the mind through Psychedelic Inspired Medicines & Experiential Therapies.

Together we can overcome.

02/26/21

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

We're Creating a New Toolset for Mental Health & Addiction

Solving for mental illness and addiction requires a novel approach

ANXIETY

Experiential Therapies

Transcending traditional mental healthcare to treat Anxiety

ADHD & ADDICTION

Psychedelic Inspired Medicines

Unlocking a new kind of healing for ADHD & Addiction

Psychedelic Innovation

Next-Gen R&D

Developing new compounds, therapies, methods and technologies to optimize patient outcomes

Advancing Psychedelic-inspired Medicines Through Clinical Trials

CLINICAL TRIALS

PRE-DISCOVERY

DISCOVERY

PRE-CLINICAL

PHASE 1A

PHASE 2A

PHASE 2B

PHASE 3

MINDMED DEVELOP (Commercial Drug Development Programs)

LSD Experiential Therapy

Anxiety - Project Lucy

PHASE 2A

18-MC

Opioid Withdrawal

PHASE 2A

LSD Microdosing

Adult ADHD

PHASE 2A

MINDMED DISCOVER (R&D Collaborations)

University Hospital Basel

LSD Assisted Therapy

Cluster Headaches

Multiple Ongoing or Completed:  on LSD, MDMA, DMT, Psilocybin

LSD Assisted Therapy

PHASE 2

Cluster Headaches

PHASE 2

Multiple Ongoing or Completed:  on LSD, MDMA, DMT, Psilocybin

PHASE 1

We’re a New Kind of Pharma Company

Patients and therapists deserve care that transcends traditional symptom management cycles, advancing long-term mental healing.

View our approach

Our Healing Goes Beyond Just A Pill

01

Discover

Rigorous science of novel psychedelic compounds, therapies, and healing technologies in collaboration with leading institutions and researchers to make faster discoveries, together

02

Develop

Conducting clinical trials of psychedelic inspired medicines and experiential therapies within existing regulatory pathways to ensure the most effective & transformative healing experience possible

03

Deploy

We hold ourselves and our products to the highest levels of safety, efficacy, and accessibility so psychedelic inspired medicines and experiential therapies can one day reach patients in need

Partnerships

Groundbreaking R&D In the Birthplace of LSD: Basel, Switzerland

Partnerships

Training a New Generation of Psychiatrists at NYU

Partnerships

Studying the Science of Microdosing with Experts at Maastricht University

Press Release

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning...

News & Press

Can LSD cure our pandemic anxiety? MindMed is spending big to find out...

Press Release

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine...

Press Release

MindMed's LSD Neutralizer Study Begins...

Press Release

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup...

More News

IN THE PRESS

This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”

Shark Tank's Kevin O' Leary MindMed Investor

MindMed named one of 36 startups that could change the world

MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”

Meet the Team

Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.

MEET MINDMED